GEN Exclusives

More »

Tutorials

More »
Oct 15, 2010 (Vol. 30, No. 18)

Next-Generation DNA Assembly Tools

Emergence of Synthetic Biology Necessitates New Solutions to Generate Molecules

  • Genome engineering has expanded to cover myriad applications including the analysis of complex pathways, the construction of new biological parts, and the re-design of existing biological systems. All these areas require the precise and concerted assembly of multiple DNA fragments of various sizes, including chromosomes.

    Current commercial cloning products are not robust enough to support the assembly of very large or very small genetic elements or a combination of both. In addition, current strategies are not flexible enough to allow further modifications to the original design without having to undergo complicated cloning strategies.

    In this article we present a set of technologies from Invitrogen, part of Life Technologies, that allow the seamless, simultaneous, flexible, and highly efficient assembly of genetic material, designed for a wide dynamic size range. The assembly can be performed either in vitro using an enzymatic mix or within the living cells.

  • In Vivo Recombineering

    Click Image To Enlarge +
    Figure 1. Features and performance of the in vivo recombineering system: (A) Map of pYES1L. SpnR, spectinomycin resistance gene, repE-sopA-sopB genes are required for replication in E. coli; ARS4-CEN5, S. cerevisiae’s chromosome II centromere; trp1, gene encoding yeast’s phosphoribosylanthranilate isomerase; oriT, F’ origin of transference; COS, bacteriophage lambda cos site. (B) YAC conversion cassette. CmR, chloramphenicol resistance gene; URA3, orotidine 5-phosphate decarboxylase gene. (C) Table indicating cloning configurations and efficiencies. (D) Linker-mediated recombinational cloning. DNA fragments (100 to 200 ng) plus 20 pmol of oligonucleotides were transformed into MaV203. DNA fragments are represented by red lines, vector by green lines, and oligonucleotides by blue lines.

    The in vivo approach requires the transformation into yeast of two or more linear DNA molecules that share unique common end sequences. End-homology can even be provided in trans by overlapping oligonucleotides. If one of the molecules harbors replication and selection elements for yeast and E. coli, then circular episomes up to 110 kilo base-pairs (kbp) in length can be assembled in yeast and transferred to E. coli for downstream applications.

    For this purpose a new vector, pYES1L, was constructed (Figure 1A). The plasmid contains a S. cerevisiae’s centromere and the trp1 gene for selection in yeast. In addition F´ ori, the spectinomycin resistance gene, an oriT, and the bacteriophage λ COS site were added for manipulation in E. coli. Rare restriction sites were added for cloning and mapping. We also designed a cassette to convert any E. coli plasmid into a YAC episome, with yeast features similar to pYES1L plus the URA3 gene as an optional counter-selectable marker (Figure 2B).

    The system was tested by simultaneously assembling up to 10 linear fragments in a predetermined order into pYES1L (Figure 1C). Adjacent DNA fragments, which shared 30 to 80 base pairs (bp) of end-homology, had been previously cloned into pACYC184 or directly amplified by PCR.

    DNA (up to 200 ng) was combined with S. cerevisiae MaV203 competent cells (trp1-901; URA3) and plated onto tryptophan-free CMS agar medium. Clones were verified by colony-PCR and sequencing and/or transferred back to E. coli by directly electroporating colony lysates for restriction profiling. Cloning efficiencies ranged from 58 to 100%.

    The approach has also been applied to recombine fragments that do not share end-homology. Here, homology is provided in trans by complementary oligonucleotides that overlap both fragments (Figure 1D). The method is advantageous for re-using fragments in a new sequence context, for cloning DNA targets that cannot be readily amplified by PCR, or for editing the fragment junctions generating end imperfections.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?